Applied Genetic Technologies Corporation And National Neurovision Research Institute (NNRI) Collaborate, Funding Research in two Genetic Retinal Diseases

Published: Jun 29, 2009

GAINESVILLE, Fla.--(BUSINESS WIRE)--Applied Genetic Technologies Corporation (AGTC), a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that AGTC has entered into an agreement with the National Neurovision Research Institute (NNRI), the clinical trial support organization for the Foundation Fighting Blindness(FFB), to collaborate in experiments using the AAV delivery system in the treatment of two genetic retinal diseases known to cause blindness at an early age. The research will be coordinated by AGTC and will be conducted at The University of Florida, Oregon Health & Science University, The University of Pennsylvania, and The University of British Columbia.

Back to news